HKMPF
HKMPF
$19.29
0.00%
No data for this timeframe.
Vol
SEC Reports1
Prev Close $19.29
Recent Activity
Jun 4, 2026
SEC
The Supreme Court unanimously reversed the Federal Circuit and dismissed Amarin's induced-infringement suit against Hikm
COURT-RULING — Impact 7/10
Jun 4, 2026
Event
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court ruling from Supreme Court of the United States. Docket: 24-889
Jun 3, 2026
Event
Olanzapine
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients wi
May 1, 2026
clinical_trial_readout
Results Pending: Piroxicam plus Counterirritant (brand name Counterpain® PXM). (Phase 3) — Completed 78d ago
Trial: Counterpain PXM Versus Diclofenac Versus Piroxicam
Sponsor: Taisho Pharmaceutical Indonesia
P
Analyst Ratings
8Strong Buy
10Buy
2Hold
1Sell
0Strong Sell
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 86% buy across 21 analysts — 8 strong buy, 10 buy, 2 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.5B | 3.5% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $3.6B | 4.8% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 10 | 2 | 1 | 0 | 86% | |
| May 1, 2026 | 8 | 10 | 2 | 1 | 0 | 86% | |
| Apr 1, 2026 | 8 | 10 | 2 | 1 | 0 | 86% | |
| Mar 1, 2026 | 7 | 10 | 2 | 1 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
Enforcement
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
Court ruling from Supreme Court of the United States. Docket: 24-889
Jun 3, 2026
Clinical Trial
Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
Phase Phase 3 — COMPLETED
Jun 3, 2026
FDA
Olanzapine
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsy
May 29, 2026
Clinical Trial
Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome
Phase Phase 2 — COMPLETED
May 29, 2026
FDA
Mitomycin
WARNINGS Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. App
May 28, 2026
Clinical Trial
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase Phase 2 — TERMINATED
May 21, 2026
Clinical Trial
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
Phase Phase 3 — TERMINATED
May 21, 2026
Clinical Trial
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Phase Phase 3 — TERMINATED
May 12, 2026
FDA
INFUMORPH 500
Unavailable: Product temporarily on backorder. (Shortage of an active ingredient) [Analgesia/Addiction]
May 12, 2026
FDA
ATIVAN
Unavailable: Estimated recovery: TBD (Other) [Neurology]
May 12, 2026
FDA
FENTANYL CITRATE
Unavailable: Additional lots will be available in the May 2026 timeframe. Product will be made available as it is released. (Demand increase for the
May 1, 2026
clinical_trial_readout
Results Pending: Piroxicam plus Counterirritant (brand name Counterpain® PXM). (Phase 3) — Completed 78d ago
Trial: Counterpain PXM Versus Diclofenac Versus Piroxicam
Sponsor: Taisho Pharmaceutical Indonesia
Phase: Phase 3 | Completed: 2026-02-12
Conditions:
Apr 3, 2026
clinical_trial_readout
Results Pending: HRS9531 Tablet (Phase 2) — Completed 85d ago
Trial: Efficacy and Safety of HRS9531 Tablet in Obese Subjects
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Phase: Phase 2 | Completed: 2026-01-08
Apr 1, 2026
clinical_trial_readout
Results Pending: Piroxicam plus Counterirritant (brand name Counterpain® PXM). (Phase 3) — Completed 48d ago
Trial: Counterpain PXM Versus Diclofenac Versus Piroxicam
Sponsor: Taisho Pharmaceutical Indonesia
Phase: Phase 3 | Completed: 2026-02-12
Conditions:
Mar 30, 2026
clinical_trial_readout
Results Pending: Piroxicam plus Counterirritant (brand name Counterpain® PXM). (Phase 3) — Completed 46d ago
Trial: Counterpain PXM Versus Diclofenac Versus Piroxicam
Sponsor: Taisho Pharmaceutical Indonesia
Phase: Phase 3 | Completed: 2026-02-12
Conditions: